DPP4 and prostate adenocarcinoma: TCGA-PRAD cohort analysis revealed a strong association between elevated DPP4 expression and poor clinical outcomes was observed through overall survival analysis (Figures 4A–D), a finding that aligns with previous reports of DPP4 overexpression in metastatic PCa (Lu et al., 2022).